Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acalabrutinib + pembrolizumab
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Acalabrutinib + pembrolizumab is an investigational combination therapy consisting of two distinct agents: acalabrutinib, a next-generation, highly selective small-molecule covalent inhibitor of Bruton tyrosine kinase (BTK), and pembrolizumab, a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) immune checkpoint. Acalabrutinib disrupts B-cell receptor signaling by inhibiting BTK, which is critical for the survival and proliferation of malignant B cells. Pembrolizumab blocks PD-1 on T cells to enhance antitumor immune responses by preventing tumor-induced T cell inactivation. The combination has been studied in phase 1/2 clinical trials for various hematologic malignancies and solid tumors such as head and neck squamous cell carcinoma (HNSCC), with the rationale that BTK inhibition may reprogram the tumor microenvironment to improve response to PD-1 blockade[1][2][5].
- Brand names
- Keytruda
- Other names
- acalabrutinib + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on acalabrutinib + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acalabrutinib + pembrolizumab.